instruction
stringlengths 22
145
| input
stringclasses 1
value | answer
stringlengths 220
325
| text
stringlengths 382
597
|
|---|---|---|---|
The role of supportive care in improving the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The effect of concurrent health conditions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) from EQUULEUS was 8.8 months with a 95% Confidence Interval (CI) of (4.6, 15.4) <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
Median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)? | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
Comparison of the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The impact of patient characteristics on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The role of genetic factors in the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The influence of previous treatments on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The correlation between the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The role of supportive care in improving the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
The effect of concurrent health conditions on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Carfilzomib+Dexamethasone (DKd) from EQUULEUS was Not Reached months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/134/5/421/273899/Daratumumab-plus-carfilzomib-and-dexamethasone-in)</sup> |
|
Median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)? | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
Comparison of the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The impact of patient characteristics on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The role of genetic factors in the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The influence of previous treatments on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The correlation between the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The role of supportive care in improving the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The effect of concurrent health conditions on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd). | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
Median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd)? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
Comparison of the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The impact of patient characteristics on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The role of genetic factors in the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The influence of previous treatments on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The correlation between the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The role of supportive care in improving the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
The effect of concurrent health conditions on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide+Bortezomib+Dexamethasone (RVd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Bortezomib+Dexamethasone (RVd) from Griffin was None months with a 95% Confidence Interval (CI) of None <sup>[1](https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and)</sup> |
|
Median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd)? | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
Comparison of the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The correlation between the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd). | The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Isatuximab+Carfilzomib+Dexamethasone (Isa-Kd) from IKEMA was NR months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
Median PFS for Carfilzomib+Dexamethasone (Kd)? | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Carfilzomib+Dexamethasone (Kd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from IKEMA was 19.15 months with a 95% Confidence Interval (CI) of (15.77, NR) <sup>[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext)</sup> |
|
Median PFS for High-Dose Melphalan? | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for High-Dose Melphalan?
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for High-Dose Melphalan with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for High-Dose Melphalan with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for High-Dose Melphalan and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for High-Dose Melphalan and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for High-Dose Melphalan. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for High-Dose Melphalan.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan from GIMEMA was 43 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for Melphalan+Prednisone+Lenalidomide (MPR)? | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Melphalan+Prednisone+Lenalidomide (MPR)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR). | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR).
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) from GIMEMA was 22.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for Lenalidomide Maintenance? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for Lenalidomide Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for Lenalidomide Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide Maintenance from GIMEMA was 41.9 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for No Maintenance? | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for No Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for No Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for No Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for No Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for No Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
Subsets and Splits